miR-145-5p Inhibits Vascular Smooth Muscle Cells (VSMCs) Proliferation and Migration by Dysregulating the Transforming Growth Factor-\(\beta\) Signaling Cascade

**Background:** There is accumulating evidence demonstrating that microRNAs (miRNA) play essential roles in proliferation, migration, and invasion of vascular smooth muscle cells (VSMCs). However, the exact function of these molecules and the mechanisms involved are not fully understood. In this study, we defined the role of miR-145-5p in VSMCs.

**Material/Methods:** This study used the PDGF-bb-induced VSMCs proliferation model. Expression of miR-145-5p and its target, Smad4, were detected and measured by real-time PCR and Western blot analysis. The luciferase reporter of miR-145-5p was used to elucidate miRNA-target interactions. The functions of miR-145-5p in proliferation and migration were detected by CCK-8 assay, Transwell assay, and scratch test.

**Results:** This study demonstrates that miR-145-5p is downregulated in PDGF-mediated VSMCs in both time- and dose-dependent manners. The in vitro results suggest that overexpression of miR-145-5p results in a reduction in SMAD4 and an increase in SMAD2, Smad3, and TGF-\(\beta\) at the mRNA and protein levels. Overexpression of miR-145-5p inhibited PDGF-induced VSMCs proliferation and migration. Moreover, SMAD4 was identified as a direct target of miR-145-5p and is involved in PDGF-mediated VSMC proliferation. Downstream factors such as Smad2, Smad3, and TGF-\(\beta\) were also influenced by miR-145-5p.

**Conclusions:** We identify miR-145-5p as a novel regulator of VSMC. Moreover, miR-145-5p inhibits VSMCs proliferation and migration by directly targeting Smad4 and dysregulating the transforming growth factor-\(\beta\) signaling cascade, including Smad2, Smad3, and TGF-\(\beta\).

**MeSH Keywords:** MicroRNAs • Muscle, Smooth, Vascular • Transforming Growth Factor beta

**Full-text PDF:** [https://www.medscimonit.com/abstract/index/idArt/910986](https://www.medscimonit.com/abstract/index/idArt/910986)
Background

Vascular smooth muscle cells (VSMCs) are recognized as an essential component of the vascular system, including arteries, veins, and microvessels, and are essential for vascular integrity, with a key role in maintaining vascular structure [1]. The endothelial layer in arterial vessels protects other tissues from harmful substances in the blood and regulates blood pressure. In pathophysiologic conditions, for example, with endothelial dysfunction or damage, VSMCs attempt to migrate to the intima and proliferate to supplement neointimal lesions [2]. Primary culture of VSMCs is a pivotal technique in in vitro models, which displays considerable plasticity and can be used to study molecular mechanisms related to a specific physiopathologic process at the cellular level, ranging from contraction [3] to proliferation [4]. The migration and proliferation of VSMCs occurs in both physiological and pathological processes [5]. Proliferation and migration of VSMCs lead to structural remodeling, which has a significant effect on the physiological processes of hypertension development [3]. These responses are influenced by miRNAs in vascular smooth muscle cells and other signaling pathways [6].

MicroRNAs (miRNAs) are now receiving increased attention due to their roles in many biological processes in both pathological and physiological states. miRNAs are recognized as endogenous, non-coding, single-stranded RNAs whose function is to bind the messenger RNAs (mRNA) of expressed genes of approximately 22 nucleotides and target them by posttranscriptional mechanisms for reduction or inhibition of translation, resulting in reduced expressed protein levels [7,8]. miRNAs play a key role in gene expression, and dysregulation of their synthesis causes many serious chronic diseases [9]. miRNAs play important roles in many physiological and pathological cellular process, such as proliferation [10–12], differentiation [13,14], migration [15], and apoptosis [15,16]. In a previous study, miR-145-5p was confirmed as a tumor suppressor in different types of cancers, such as gastric [17], breast [18], and prostate [19] cancers, and is associated with cancer metastasis [20]. Potential mechanisms have been investigated as miR-145-5p regulates the proliferation and migration by modulating various signal pathways, such as inhibiting the MAPK and PI3K/AKT pathways [21,22].

Based on the description above, accumulating evidence has shown that miR-145 plays a critical role in various diseases. A previous study has indicated that miR-145 is downregulated in dedifferentiated VSMCs, and is also a critical modulator of VSMCs proliferation and migration [23]. Additionally, overexpression of miR-143/145 promotes cells differentiation and inhibits the proliferation of VSMCs [24].

Characterizing the role of miR-145-5p and TGF-β-regulated genes associated with vascular smooth muscle cells proliferation and migration can identify therapeutic targets and diagnostic markers. However, there has been no research exploring the potential relationship between miR-145-5p and TGF-β cascade in the proliferation and migration of VSMCs. Therefore, in the present study, we assessed the role of miR-145-5p, TGF-β signaling, and TGF-β-regulated genes on the development of proliferation and migration by using the PDGF-bb-induced VSMCs proliferation model.

Material and Methods

Cell culture and treatment

VSMCs were acquired from ATCC and cultured and maintained in DMEM supplemented with 10% fetal bovine serum (FBS). At the same time, 100 U/ml penicillin and 100 μg/ml streptomycin, epidermal growth factor 25 ng/ml, and basic fibroblast growth factor 10 ng/ml were added until confluent. VSMCs were grown to approximately 90% confluence in 75-cm² culture flasks. The culture temperature was maintained at 37°C in an incubator containing 5% CO₂. The culture medium was changed every 3 days. For dissociation, the cells were dissociated with 0.025% trypsin and 0.1% EDTA every week. PDGF-bb (Promega) was added at 20 ng/mL concentration.

Measurement of cell proliferation in vitro

Cell proliferation was measured by using CCK-8 cell viability assay. Briefly, approximately 5×10³ VSMCs were distracted into each well of a 96-well plate, and cultured in an incubator at 37°C. The next day, VSMCs were transferred into 100 μl medium containing 10% fetal bovine serum at indicated concentrations and incubated for 30 h. After that, 10 μl CCK-8 reagent was added into each well of the 96-well plate and incubated at same temperature for 4 h. Finally, the 96-well plate plates were shaken for 10 min and the OD values were read at 450 nm.

Measurement of cell migration in vitro

For measurement of migration, we used the wound healing assay and the Transwell migration assay. Wound healing assays were used as follows: VSMCs were cultured in 10% FBS-DMEM, then the serum in the medium were deprived for 18 h. Later, the confluent monolayer was scratched with a sterile pipette tip. After that, the VSMCs were washed with PBS and fresh medium was added. VSMCs were cultured and maintained in a stable and suitable environment for 24 h. Migration was measure by phase-contrast microscopy at different time points up to wound healing closure.
Transwell migration assay was conducted by following the manufacturer’s protocol. Briefly, the cells migrating through the Transwell membrane were fixed with 3.7% paraformaldehyde. The images of the migrating cells stained with crystal violet were obtained using a Nikon Eclipse microscope with a Nikon DSR1 camera. The number of migrating cell was counted with ImageJ software.

**Plasmids and miRNA transfection**

Potential target mRNAs of miR-145-5p were roughly searched on 3 websites including [http://www.targetscan.org/](http://www.targetscan.org/), [http://www.microrna.org/](http://www.microrna.org/), and [http://mirdb.org/](http://mirdb.org/). miR-145-5p mimics and inhibitors were purchased from Ambion (mirVana miR-145-5p mimic: MC11051; mirVana miR-145-5p inhibitor: MH11051). After 24 h of transfection, total RNA and protein were extracted from the cells and assessed using qRT-PCR and Western blot analysis, respectively.

**Luciferase assay**

We cultured 1×10⁵ HEK293 cells, then transfected them with Smad 4 R1-3’UTR-wt or Smad4-3’UTR-mt and mi-145-5p using Lipofectamine 2000 (Invitrogen, USA) according to the protocol previously described. Luciferase was measured 24 h after transfection by using the Dual Luciferase Reporter Assay System (Promega) and normalized to Renilla luciferase activity.

**Flow cytometry**

VSMCs were incubated with culture medium for 24 h after transfection with miR-145-5p mimics, inhibitor, or negative control. For apoptosis measurements, VSMCs were collected, washed with PBS, resuspended in 100 μl of 1× binding buffer, and stained with 5 μl Annexin V and 5 μl of PI (Becton-Dickinson) at room temperature for 15 min in the dark. After that, we performed cell cycle analysis, in which VSMCs were washed with cold PBS and fixed with 70% ethanol overnight at −20°C. Fixed cells were rehydrated in PBS for 10 min and subjected to PI/RNase staining. A flow cytometer was utilized to evaluate the apoptotic levels and cell cycle in each sample, following the manufacturer’s protocol.

Figure 1. miR-145-5p is inhibited by PDGF-bb in VSMCs. (A) PDGF-bb induce VSMCs proliferation time-dependently. (B) PDGF-bb induced VSMCs proliferation dose-dependently. (C) The expression of miR-145-5p was measured by qRT-PCR, showing that miR-145-5p was downregulated. (D) The expression of miR-145-5p was measured by qRT-PCR, showing that miR-145-5p was downregulated. * p<0.05, ** p<0.01, and *** p<0.001.
RNA isolation and PCR

Total RNA was isolated from VSMCs samples using Trizol reagent (Invitrogen, USA) and quantified by absorbance at 260 nm. One microgram of RNA was used to perform the reverse transcription with a High-Capacity cDNA Archive kit (Applied Biosystems, USA). Finally, real-time PCR was performed on an ABI Prism 7500 fast sequence detection PCR system (Applied Biosystems) according to the manufacturer’s instructions, and after the process, ΔΔCt method was used to analyze the data.
Western blotting

Western blot methods were performed on protein extracts from VSMCs as previously described. Briefly, VSMCs were lysed with ice-cold RIPA buffer and supplemented with a protease inhibitor cocktail (Sigma-Aldrich). Later, equal amounts of extracts (30 µg) were electrophoresed on a sodium dodecyl sulfate (SDS) polyacrylamide gel and electroblotted to nitrocellulose filter membranes (Millipore). Then, membranes were immersed in blocking buffer with 5% nonfat milk powder for 1 h and incubated with antibodies against Smad3, Smad2, Smad4, PNCA, TGFβ, or GAPDH overnight at 4°C. Finally, they were incubated with horseradish peroxidase-conjugated secondary antibodies and the protein bands were visualized using the Super Signal chemiluminescent detection module.

Statistical analysis

All data were analyzed using GraphPad Prism 5.1 software. Results are expressed as the mean ± standard deviation. When only 2 groups were compared, the double-sided t test was used to assess statistical differences. Significant statistical differences between groups were analyzed using one-way ANOVA. P value less than 0.05 (p<0.05) was considered statistically significant.

Results

miR-145-5p is suppressed by PDGF-bb in VSMCs

First, we examine the VSMCs proliferation using CCK8 assay. PDGF-bb induced VSMCs proliferation in time-dependent and dose-dependent manners (Figure 1A, 1B). Then, we assessed the miR-145-5p in VSMCs which treated by PDGF-bb. The results demonstrated that miR-145-5p was downregulated after using PDGF-bb (Figure 1C, 1D).

miR-145-5p diminishes the PDGF-mediated VSMCs proliferation

To assess the function and molecular mechanism of miR-145-5p in VSMCs, we used miR-145-5p mimics and inhibitors. miR-145-5p expression was increased in VSMCs transfected with miR145-5p mimics (Figure 2A) and decreased in VSMCs transfected with miR-145-5p inhibitor (Figure 2C). For proliferation, the results of CCK-8 assay demonstrated that the growth rate of VSMCs was decreased in cells transfected with miR-145-5p mimics compared with cells transfected with scramble mimics or that were untreated (Figure 2B). In the meantime, miR-145-5p inhibitor enhanced the VSMCs proliferation.
proliferation compared with scramble and untreated groups (Figure 2D). We also confirmed that overexpression of miR-145-5p inhibited both mRNA and protein expression of PCNA in VSMCs (Figure 2E, 2F).

Overexpression of miR-145-5p attenuates migration of VSMCs

VSMCs migration is an essential component of atherogenesis and neointimal formation, in which the vessel wall is being re-modeled [25]. Thus, we investigated whether miR-145-5p affected migration of VSMC. The wound healing assay and Transwell migration assay were used. Transfection of miR-145-5p mimic attenuated wound closure, which indicates reduced cell motility. In contrast, miR-145-5p inhibitor potentiated potential cellular movement (Figure 3A). The effects of miR-145-5p mimic and inhibitor on cellular migration were quantified by measuring the cell-free area (Figure 3B). The results demonstrated that miR-145-5p attenuates migration of VSMCs. A Transwell migration assay also revealed that miR-145-5p negatively influences cell movements (Figure 3C, 3D).

miR-145-5p targeted Smad4 in VSMCs

To evaluate the underlying further mechanisms of the suppressive effects of miR-145-5p on VSMCs proliferation, we used different bioinformatics methods to help find the target genes of miR-145-5p. Among the targets predicted by TargetScan, miRanda, and miRDB, Smad4 was the gene that was localized at the 3 main centers of the net-comprised genes (Figure 4A, 4B).
To confirm that miR-145-5p can regulate Smad4 expression by directly binding to the Smad4 3’-UTR, we generated luciferase reporter constructs containing specific mutations at the putative miR-145-5p binding site. As shown in Figure 4C, when cells were transfected with the wild-type Smad4 3’-UTR, co-transfection of miR-145-5p mimics inhibited luciferase activity. The result shows that miR-145-5p binds directly to the putative Smad4 3’-UTR regions predicted. Moreover, we found that both protein and mRNA levels of Smad4 increased in VSMCs transfected with miR-145-5p mimics and decreased in VSMCs transfected with miR-145-5p inhibitors (Figure 4C, 4D).

Overexpression of miR-145-5p repressed the Smad1, Smad2, and TGF-β expression. (A) Expression of Smad1, Smad2, and TGF-β were detected using Western blotting. GAPDH was used as a loading control. (B) The mRNA expression of Smad1 was detected using qRT-PCR. (C) The mRNA expression of Smad2 was detected using qRT-PCR. (D) The mRNA expression of TGF-β was detected using qRT-PCR. * p<0.05, ** p<0.01, and *** p<0.001.

To confirm that miR-145-5p can regulate Smad4 expression by directly binding to the Smad4 3’-UTR, we generated luciferase reporter constructs containing specific mutations at the putative miR-145-5p binding site. As shown in Figure 4C, when cells were transfected with the wild-type Smad4 3’-UTR, co-transfection of miR-145-5p mimics inhibited luciferase activity. The result shows that miR-145-5p binds directly to the putative Smad4 3’-UTR regions predicted. Moreover, we found that both protein and mRNA levels of Smad4 increased in VSMCs transfected with miR-145-5p mimics and decreased in VSMCs transfected with miR-145-5p inhibitors (Figure 4C, 4D).

**Overexpression of miR-145-5p suppressed growth factor production**

We conducted Western blot and RT-PCR analyses to detect the downstream signaling molecules Smad3, SMAD2, and TGF-β in the presence or absence of Smad4, scramble, or miR-145-5p, respectively. According to Western blot results, Smad3, Smad2, and TGF-β protein expression decreased with the treatment of miR-145-5p compared with scramble (Figure 5A). The results of RT-PCR showed that Smad4 enhanced the mRNA expression of Smad3, Smad2, and TGF-β. However, after miR-145-5p treatment, Smad3, Smad2, and TGF-β proteins and mRNA were significantly downregulated in the VSMCs (Figure 4B–4D).

**Smad4 has a critical role in miR-145-5p-mediated VSMCs proliferation**

We further investigated whether Smad4 was responsible for VSMCs proliferation after regulating miR-145-5p expression. We used the VSMCs co-transfected with either miR-145-5p mimic or scramble and si-Smad4 or pcDNA empty vector, and CCK-8 proliferation assay, flow cytometric analysis, wound healing assays and Western blotting were also used. As shown in Figure 6A–6D, when miR-145-5p mimic and si-Smad4 were co-transfected into VSMCs, miR-145-5p expression significantly suppressed the VSMCs proliferation in CCK-8 proliferation assay, flow cytometric analysis, and wound healing assays. Furthermore, PCNA protein levels were correlated with both miR-145-5p and Smad4 (Figure 6E). These results indicate that Smad4 has a critical role in miR-145-5p-mediated VAMCs proliferation.
miR-145-5p is considered to be a tumor suppressor and a critical regulator of human stem cell growth and differentiation. Previous reports showed low levels of miR-145-5p in colon [26,27], breast [28], prostate [29], and ovarian [30] cancers. Furthermore, many miR-145-5p target genes have been confirmed, such as ISR-1, p70S6K1, ER, RTKN, and ZEB2. In the present study, we identified a novel role of miR-145-5p in the regulation of the transforming growth factor-β signaling cascade, showing that overexpression of miR-145-5p led to a remarkable decrease in Smad4 gene expression, which is a key signaling molecule of the TGF-β/Smads pathway. Exogenous overexpression of miR-145 effectively suppressed the high glucose-induced excessive proliferation and migration of VSMCs and ROCK1 as a downstream target gene product of miR-145 [31].

This signaling pathway is found among patients with vascular disorders, indicating the essential role of TGF-β pathways in vascular homeostasis. TGF-β is an important member of the TGF-β superfamily, which includes activins, inhibins, growth and differentiation factors, and bone morphogenetic proteins. For many diseases, such as colorectal [32], breast, prostate, and hepatocellular [33] cancers, TGF-β plays an essential role in regulating cell proliferation and migration. The TGF-β signaling pathway takes part in many physiological and pathological processes and plays a pleiotropic role in diverse functions.
Figure 6. SMAD4 has a critical role in miR-145-5p-mediated VSMCs proliferation. (A) CCK analysis of cell proliferation in VSMCs with either miR-145-5p inhibitor or scramble and si-Smad4 or pcDNA empty vector. (B) CCK analysis of cell proliferation in VSMCs with either miR-145-5p mimic or scramble and si-Smad4 or pcDNA empty vector. (C) Flow cytometric analysis of apoptosis in VSMCs transfected with miR-145-5p inhibitors, miR-145-5p inhibitors/si-Smad4, and control. (D) Flow cytometric analysis of apoptosis in VSMCs transfected with miR-145-5p mimics, miR-145-5p mimics/Smad4, and control. (E) Wound healing assays in VSMCs transfected with miR-145-5p inhibitors, miR-145-5p inhibitors/si-Smad4 and control. (F) Wound healing assays in VSMCs transfected with miR-145-5p mimics, miR-145-5p mimics/Smad4, and control. (G) Western blot detection of PCNA protein in VSMCs upon transfection of miR-145-5p inhibitors, miR-145-5p inhibitors/si-Smad4, miR-145-5p mimics, miR-145-5p mimics/Smad4, and control. * p<0.05, ** p<0.01, and *** p<0.001.

of diseases, including embryogenesis [34], immune responses [35], Fanconi anemia [36], and diabetes [37]. The association of TGF-β1 and Smad is well understood and is considered to be an important pathway in many pathophysiological processes [38]. However, a potential role for Smad transcription factors in TGF-β1 cascade has never been investigated [39,40]. In the present study, we focused on the key regulator Smad4 in the TGF-β/Smads pathway. Smad4, as a member of the Smads family of signal transducers from TGF-β, mediates proliferation and apoptosis in many cell lines [41–43]. In VMSCs,
Zhang et al. indicating that Smad4-dependent TGF-β signaling in VSMCs protects against aortic aneurysm formation and dissection [43]. Other members of the Smads family, including Smad3, Smad2, and Smad1, share similar structures. Despite their similarities, Smad2 and Smad3 have differential roles in TGFβ signal transduction. For example, Smad2 knockout mice die during gastrulation [44,45], and Smad3 knockout mice develop cartilage for several months after birth [46,47]. However, they both play essential roles in the transforming growth factor-β signaling cascade.

In our study, firstly, we identified that miR-145-5p diminishes the PDGF-mediated VSMCs proliferation and migration by CCK-8 assay. To further identify the molecular mechanism by which miR-145-5p regulates VSMCs migration and proliferation, we searched for potential target genes of miR-145-5p via microRNA.org, TargetScan, and miRDB. The results of Luciferase assay demonstrated that Smad4 was a direct target of miR-145-5p. Western blotting assay and RT-PCR revealed that overexpression of miR-145-5p resulted in the downregulation of Smad4 at protein and mRNA levels. Many factors in the TGF-β1/Smad cascade, including Smad3, Smad2, and TGF-β protein expression, were influenced by overexpression of miR-145-5p, indicating that miR-145-5p also plays an important role in the TGF-β1/Smad cascade. Finally, we used si-Smad4 and miR-145-5p mimic to co-transfect VSMCs, indicating that Smad4 has a critical role in miR-145-5p-mediated VAMCs proliferation. miR-145 is overexpressed in exercise, remodels arterioles in hypertension, and induces VSMCs to maintain a contractile phenotype, in which miR-145 appears to be involved by inversely regulating Akt signaling via its upstream signal [48].

Conclusions

We demonstrated that miR-145-5p inhibited cell proliferation and suppressed migration and invasion in VSMCs in vitro. Furthermore, miR-145-5p performs a biological function through directly targeting Smad4 and influences the TGF-β1/Smad cascade. Thus, miR-145-5p plays suppressive roles in VSMCs. Our findings open new avenues for the study of the TGF-b-family signaling cascade and miRNA biogenesis regulation and suggests that miR-145-5p/Smad4 is a promising prognostic and therapeutic target in vascular disease.

Conflicts of interest

None.

References:

1. Chen Q, Zhang H, Liu Y et al: Endothelial cells are progenitors of cardiac pericytes and vascular smooth muscle cells. Nat Commun, 2016; 7: 12422
2. Wang G, Jacquet L, Karamariti E, Xu Q: Origin and differentiation of vascular smooth muscle cells. J Physiol, 2015; 593: 3013–30
3. Brozovich FV, Nicholson CJ, Degen CV et al: Mechanisms of vascular smooth muscle contraction and the basis for pharmacologic treatment of smooth muscle disorders. Pharmacol Rev, 2016; 68: 476–532
4. Montezano AC, Lopes RA, Neves KB et al: Isolation and culture of smooth vascular smooth muscle cells from small and large vessels. Methods Mol Biol, 2017; 1527: 349–54
5. Aragona M, Dekoninck S, Rulands S et al: Defining stem cell dynamics and migration during wound healing in mouse skin epidermis. Nat Commun, 2017; 8: 14684
6. Schlosser A, Pilecki B, Hemstra LE et al: MPP4 promotes vascular smooth muscle cell proliferation, migration and accelerates neointima formation. Arterioscler Thromb Vasc Biol, 2016; 36: 122–33
7. Li CY, Liang GY, Yao WZ et al: Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression. Clin Transl Oncol, 2017; 19: 162–72
8. Freitas RC, Bortolin RH, Lopes MB et al: Integrated analysis of miRNA and mRNA gene expression microarrays: Influence on platelet reactivity, clopidogrel response and drug-induced toxicity. Gene, 2016; 593: 172–78
9. McManus DD, Rong J, Huan T et al: Messenger RNA and MicroRNA transcriptomic signatures of cardiometabolic risk factors. BMC Genomics, 2017; 18: 139
10. Kim DY, Sung JH: Regulatory role of microRNAs in the proliferation and differentiation of adipose-derived stem cells. Histol Histopathol, 2017; 32: 1–10
11. Xia W, Zhou J, Luo H et al: MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7. Cancer Cell Int, 2017; 17: 14
12. Xie L, Sadowsky Y: The function of miR-519d in cell migration, invasion, and proliferation suggests a role in early placentaion. Placenta, 2016; 48: 34–37
13. Chen X, Shi C, Wang C et al: The role of miR-497-5p in myofibroblast differentiation of LR-MSCs and pulmonary fibrogenesis. Sci Rep, 2017; 7: 40958
14. Hu F, Sun B, Xu P et al: MiR-218 induces neuronal differentiation of ASCs in a temporally sequential manner with fibroblast growth factor by regulation of the Wnt signaling pathway. Sci Rep, 2017; 7: 39427
15. Chen JH, Yang R, Zhang W, Wang YP: Functions of microRNA-143 in the apoptosis, invasion and migration of nasopharyngeal carcinoma. Exp Ther Med, 2016; 12: 3749–55
16. Li J, Mao X, Wang X et al: MiR-433 reduces cell viability and promotes cell apoptosis by regulating MACC1 in colorectal cancer. Oncol Lett, 2017; 13: 81–88
17. Jiang SB, He Xi, Xia Yi et al: MicroRNA-145-5p inhibits gastric cancer invasiveness through targeting N-cadherin and ZEB2 to suppress epithelial-mesenchymal transition. Onco Targets Ther, 2016; 9: 2305–15
18. Murti P, Sacconi A, Hossain A et al: Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study. Cancer Epidemiol Biomarkers Prev, 2014; 23: 2471–81
19. Ozen M, Karatas OF, Gullugolu S et al: Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer Invest, 2015; 33: 281–58
20. Donzelli S, Mori F, Bellissimo T et al: Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget, 2015; 6: 35183–201
21. Liu S, Gao G, Yan D et al: Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer Med, 2017; 76: 87–95
22. Yuan M, Zhang L, You F et al: MiR-145-5p regulates hypoxia-induced inflammatory response and apoptosis in cardiomyocytes by targeting CD40. Mol Cell Biochem, 2017; 413: 87–95
23. Jiang Y, Zhang M, He H et al: MicroRNA/mRNA profiling and regulatory network of intracranial aneurysm. BMC Med Genomics, 2013; 6: 1527: 349–54
24. Donzelli S, Mori F, Bellissimo T et al: Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget, 2015; 6: 35183–201
25. Liu S, Gao G, Yan D et al: Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer Med, 2017; 76: 87–95
26. Yuan M, Zhang L, You F et al: MiR-145-5p regulates hypoxia-induced inflammatory response and apoptosis in cardiomyocytes by targeting CD40. Mol Cell Biochem, 2017; 413: 87–95
27. Jiang Y, Zhang M, He H et al: MicroRNA/mRNA profiling and regulatory network of intracranial aneurysm. BMC Med Genomics, 2013; 6: 35183–201
28. Jakob P, Landmesser U: Role of microRNAs in stem/progenitor cells and cardiovascular repair. Cardiovasc Res, 2012; 93: 614–22
25. Gerthoffer WT: Mechanisms of vascular smooth muscle cell migration. Circ Res, 2007; 100: 607–21
26. Michael MZ, O’Connor SM, Pellekaan NGvH et al: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 2003; 1: 882–91
27. Xu Q, Liu LZ, Qian X et al: miR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res, 2012; 40: 761–74
28. Spizzo R, Nicoloso MS, Lupini L et al: miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ, 2010; 17: 246–54
29. Ren D, Min Wang, Guo W et al: Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res, 2014; 358: 763–78
30. Liang H, Jiang Z, Xie G, Lu Y: Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour Biol, 2015; 36: 5305–13
31. Chen M, Zhang Y, Li W, Yang J: MicroRNA-145 alleviates high glucose-induced proliferation and migration of vascular smooth muscle cells through targeting ROCK1. Biomed Pharmacother, 2018; 99: 81–86
32. Calon A, Espinet E, Palomo-Ponce S et al: Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell, 2012; 22: 571–84
33. Yuan JH, Yang F, Wang F et al: A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell, 2014; 25: 666–81
34. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003; 425: 577–84
35. Gu AD, Zhang S, Wang Y et al: A critical role for transcription factor Smad4 in T cell function that is independent of transforming growth factor beta receptor signalling. Immunity, 2015; 42: 68–79
36. Zhang H, Kozono DE, O’Connor KW et al: TGF-beta inhibition rescues hematopoietic stem cell defects and bone marrow failure in fanconi anemia. Cell Stem Cell, 2016; 18: 668–81
37. Araujo EP, de Souza CT, Veloso LA: Atypical transforming growth factor-beta signaling in the hypothalamus is linked to diabetes. Nat Med, 2014; 20: 985–87
38. Hu ZC, Shi F, Liu P et al: TIEG1 represses Smad7-mediated activation of TGF-beta1/Smad signaling in keloid pathogenesis. J Invest Dermatol, 2017; 76: 776–84
39. Ebel ME, Kansas GS: Functions of Smad transcription factors in TGF-beta1-induced selectin ligand expression on murine CD4 Th cells. J Immunol, 2016; 197: 2627–34
40. Lan HY: Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci, 2011; 7: 1056–67
41. Xia X, Wu W, Huang C et al: SMAD4 and its role in pancreatic cancer. Tumour Biol, 2015; 36: 111–19
42. Xu F, Liu C, Zhou D, Zhang L: TGF-beta/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem, 2016; 64: 157–67
43. Zhang P, Hou S, Chen J et al: Smad4 deficiency in smooth muscle cells initiates the formation of aortic aneurysm. Circ Res, 2016; 118: 388–99
44. Waldrip WR, Bikoff EK, Hoodless PA et al: Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell, 1998; 92: 797–808
45. Nomura M, Li E: Smad2 role in mesoderm formation, left–right patterning and craniofacial development. Nature, 1998; 393: 786–89
46. Furumatsu T, Ozaki T, Asahara H: Smad3 activates the Sox9-dependent transcription on chromatin. Int J Biochem Cell Biol, 2009; 41: 1198–204
47. Zhu Y, Richardson JA, Parada LF, Graff JM: Smad3 mutant mice develop metastatic colorectal cancer. Cell, 1998; 94: 703–14
48. Liao J, Zhang Y, Wu Y et al: Akt modulation by miR-145 during exercise-induced VSMC phenotypic switching in hypertension. Life Sci, 2018; 199: 71–79